Notch signaling in the pathogenesis, progression and identification of potential targets for cholangiocarcinoma (Review)

PEERANATE VANAROJ1, WANNA CHAIJAROENKUL1 and KESARA NA-BANGCHANG1,2

1Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University; 2Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thammasat University, Paholyothin, 12120 Thailand

Received September 3, 2021; Accepted January 3, 2022

DOI: 10.3892/mco.2022.2499

Abstract. Cholangiocarcinoma (CCA) is an aggressive type of bile duct cancer that is characterized by a high mortality rate due to its late diagnosis and ineffective treatment. The aim of the present systematic review was to analyze the association between Notch signaling and CCA in terms of its pathogenesis, progression and potential treatment targets. Relevant information was gathered from the PubMed, ScienceDirect and Scopus databases using the search terms ‘cholangiocarcinoma’ AND ‘Notch signaling’. Of the 90 articles identified, 28 fulfilled the eligibility criteria and were included in the analysis. It was concluded that overexpression/upregulation of Notch ligands, such as Jagged1 and Notch receptors (Notch1, Notch2 and Notch3), as well as upregulation of the upstream Notch signaling pathway, promoted CCA development and progression. In addition, downregulation of Notch1 signaling through several possible interventions appears to be a promising strategy for inhibition of CCA development and progression. Therefore, the Notch signaling pathway may be considered as a potential target for CCA control.

Introduction

Cholangiocarcinoma (CCA) is a bile duct cancer with a high mortality rate. A significant proportion of the CCA cases and resultant mortalities worldwide are reported in the north-eastern region of Thailand, where the major risk factor is infection by the liver fluke Opisthorchis viverrini through the consumption of improperly cooked cyprinoid fish that contain the parasite (1). There are currently no specific biomarkers for early detection of early-stage CCA, and patients are usually diagnosed when the disease has already progressed to the advanced stage, resulting in a poor prognosis. Liver resection is the standard therapy, but is not suitable for all cases. The 5-year survival rate following liver resection is <20%, depending on the aggressiveness, metastatic propensity and invasiveness of the tumors. Furthermore, CCA is resistant to chemotherapy and radiation (2). Investigation of the molecular mechanisms underlying the pathogenesis and progression of CCA has been an ongoing research focus, and several signaling molecules and pathways have been demonstrated to be involved in the pathogenesis and progression of CCA (3).

The Notch signaling pathway has been proposed as a conservative pathway that plays a key role in cell differentiation, proliferation and apoptosis (4). This signaling pathway is associated with several receptors and ligands. The four identified receptors are Notch1, Notch2, Notch3 and Notch4. The two families of ligands involved are the Delta-like family (DLL1, DLL3 and DLL4), and the Jagged family (Jagged1 and Jagged2). The activation of Notch signaling relies on two proteolytic enzymes in the a disintegrin and metalloprotease (ADAM) families and γ-secretase enzyme, which cleaves Notch receptors into two domains, i.e., Notch extracellular domain (NECD) and Notch intracellular domain (NICD). Following cleavage, NICD translocates to the nucleus and binds to transcription factors to promote expression of target genes, such as members of the hairy and enhancer of split (Hes) and Hes-related to YRPW motif (Hey) families (5).

Overexpression of Notch signaling genes is associated with the proliferation of certain cancers, including ovarian and breast cancers and glioma (6-8). However, overexpression of Notch signaling genes can also result in cancer cell apoptosis, such as in cases of liver cancer, small cell lung cancer and melanoma (9-11). The Notch signaling pathway in CCA cells is summarized in Fig. 1. The objectives of the present systematic review were to analyze the association of Notch signaling with the pathogenesis and progression of CCA, and uncover potential molecular targets for CCA control.

Materials and methods

The present systematic review was performed by combining the search results from three databases, i.e., PubMed, ScienceDirect and Scopus. The search terms applied were

Correspondence to: Dr Kesara Na-Bangchang, Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University, 99 Moo 18, Paholyothin Road, Klonglung, Pathumthani, 12120 Thailand
E-mail: kesaratmu@yahoo.com

Key words: cholangiocarcinoma, Notch signaling, Notch1, Notch2, Notch3
‘cholangiocarcinoma’ AND ‘Notch signaling’. All articles were retrieved and downloaded to the EndNote X9 database (Thomson Reuters Company, Canada) for further analysis. They were initially screened by titles and abstracts to exclude irrelevant articles (those not involving CCA or the Notch signaling pathway). Full-text articles included after the initial screening were further evaluated by applying the predefined eligibility criteria. The inclusion criteria were as follows: i) Articles published between January 2004 and March 2020; ii) articles available as full-text articles in English; and iii) articles with \textit{in vitro} or \textit{in vivo} studies related to the Notch signaling pathway in CCA alone or CCA and hepatocellular carcinoma (HCC). The exclusion criteria were as follows: i) Articles related to other diseases or types of cancer; ii) articles related to pathways other than Notch signaling; iii) duplicated articles; or iv) review articles, letters to the editor, editorials, systematic analyses or meta-analyses.

Two reviewers extracted data independently and disparities were resolved by discussion and suggestions from the third reviewer. The information extracted for analysis included: First author's name and year of publication, objective(s) of the study, type of Notch receptor investigated, type of study (\textit{in vitro}, \textit{in vivo} and \textit{ex vivo}), type of cell lines or animals used, laboratory techniques used, and key results and conclusions.

Results

A total of 89 articles from PubMed, ScienceDirect and Scopus databases were downloaded to the EndNote database. A total of 54 articles were excluded, and further analysis of the titles and abstracts of the remaining 36 articles led to the exclusion of 8 articles (5 articles unrelated to CCA, and 3 articles unrelated to the Notch signaling pathway in CCA). Finally, 27 articles were included in the analysis. The flow diagram of the study selection process is presented in Fig. 2, and the study summary is provided in Tables I and II. The associations of Notch1 and Notch2 signaling with CCA development and progression were investigated in 6 articles each, while those of Notch3 and Notch4 signaling were investigated in 3 and 1 article(s), respectively. The investigations involved \textit{in vitro} (n=8), \textit{in vivo} (n=12) and \textit{ex vivo} (n=8) studies. The effects of modulators of Notch signaling as potential chemotherapeutic targets for CCA were investigated in 10, 5, 3 and 3 articles for Notch1, Notch2, Notch3 and Notch4 signaling pathways, respectively. The investigated modulators included cinobufagin, verteporfin-photodynamic therapy (PDT), \(\gamma\)-secretase inhibitor (GSI), \(\gamma\)-secretase inhibitor IX, endocannabinoids, corilagin, short hairpin (sh)RNA, and small-molecule inhibitors (SMIs) of aspartate-\(\beta\)-hydroxylase, anti-Notch1,2,3 and Jagged1, microRNA (miRNA)-34a, PIK3-catalytic subunit alpha (PIK3CA), PIK75, verteporfin, FLI-06, microfibrillar-associated protein 5 (MFAP5), ALW-II-41-27, ephrin A1, lymphotoxin \(\beta\) receptor (LT\(\beta\)R), xanthohumol and \(\gamma\)-secretase inhibitor N-[\(\text{N}-(3,5\text{-di}-\text{fluorophenacetyl}-L\text{-alanyl}]\)-S-phenylglycine t-butyl ester (DAPT) (Table II).

Discussion

A summary of the currently available information on the association between Notch signaling and the pathogenesis and progression of CCA, including modulators (inhibitors or stimulators) of the signaling pathway as potential candidates for CCA chemotherapeutics, is presented in Fig. 3.

Upregulation of Notch signaling has been proposed as the mechanism associated with the transformation of mature hepatocytes into CCA cells (12-14). Nevertheless, activation of Notch signaling in hepatic progenitor cells, but not the transformation of hepatocytes, is proposed as the mechanism underlying CCA development (15). Increased expression of Notch1 has been linked to CCA development and progression (14,16-24). Notch1 has also been associated with cyclin E, the coordinate regulator protein in the G1 phase of the cell cycle; additionally, cyclin E can induce DNA damage (15). Increased NICD1 expression has also been associated with CCA development and progression through upregulation of cyclin E-associated DNA damage (15,25). Furthermore, Notch1 and Notch2 signaling have been reported to play a critical role in CCA formation (12-14,24,26-29), in which Jagged1 is the specific ligand. Upregulation of PIK3CA, AKT, and Jagged1 directly activates Notch 2 signaling and induces CCA development. Overexpression of Jagged1 enhances Notch2 signaling (26), while anti-Jagged1 treatment suppresses Notch2 signaling (27,28,30,31). At this time, the information on Notch3 and its role in CCA development and progression are limited (24,32). Notch4 signaling has also been reported to promote the development of intrahepatic CCA (ICC) and is associated with a poor survival rate (24).

The activation of upstream Notch signaling molecules, including Yes-associated protein (YAP), AKT, mTOR, SNAIL and PIK3CA, are key processes that stimulate CCA formation through the transformation of mature hepatocytes into CCA cells (12). AKT is the main upstream Notch signaling molecule, which upregulates Notch1 and Notch2 (12-14,26,27,29,33). mTOR is another upstream activator of the Notch1 receptor (12,16). YAP is an upstream signaling molecule for both AKT and mTOR (12), and co-expression of YAP with AKT induces CCA development through activating Notch signaling via the Notch2 receptor and Jagged1 ligand (12,14,28,34), or with co-expression of NICD and shp53 (shRNA of p53) (35). Co-expression of AKT and Ras (the protein product of the oncogene KRAS2), on the other hand, induces tumorigenesis (21,27,29). MFAP5, enhanced green fluorescent protein-positive cells, mTOR and AKT, activate Notch signaling by increasing Notch1 expression, thereby enhancing CCA cell proliferation (12,16,17). Modulation of mutant genes, such as p53 (inactivation), isoctrate dehydrogenase1 (activation), or other pathways, such as the Wnt (\(\beta\)-catenin) pathway (activation), and the Myc pathway (activation) with co-expression of Notch signaling (activation) has been reported to induce CCA development (14,25,33,36). Upregulation of Notch1 expression may also be caused by additional factors, such as a high expression level of prese-nilin 1 (37). Aspartate \(\beta\)-hydroxylase (ASPH) enhances activation of Notch signaling and stimulates CCA cell proliferation and migration. A high expression level of Notch1 can activate Ras-related C3 botulinum toxin substrate 1, which promotes CCA cell invasion and migration. ephrin type-A receptor 2 enhances the expression level of Notch1 and promotes CCA growth through the activation of AKT/RAS and by promoting lymphatic metastasis in ICC (21).
Figure 1. Notch signaling pathway in CCA cells. Notch ligands, such as members of the DLL or the JAG family, attach to the Notch receptors to activate the ADAM and γ-secretase enzymes. The ADAM cleaves NECD outside the cell membrane and the γ-secretase enzyme cleaves the NICD inside of the cell membrane. After being cleaved, the NICD translocates to the nucleus and interacts with the DNA-binding protein to promote expression of the target genes, such as Hes and Hey, which are associated with proliferation, migration and invasion of CCA cells. CCA, cholangiocarcinoma; Hes, hairy and enhancer of split; Hey, Hes-related to YRPW motif; ADAM, a disintegrin and metalloprotease; NECD, Notch extracellular domain; NICD, Notch intracellular domain; DLL, delta-like family; JAG, Jagged family.

Figure 2. Flow diagram of study identification and selection process. A total of 90 articles were selected by the title and abstract by using the key words ‘cholangiocarcinoma’ AND ‘Notch signaling.’ A total of 54 articles were excluded (duplication, review articles, or non-full-text articles). A total of 8 articles were further excluded by the titles and abstracts, and 24 articles were finally included in the analysis.
Table I. Studies related to Notch signaling and pathogenesis and progression of CCA.

| Author (year) | Objective to investigate | Notch type | Study type | Cell/animal used | Techniques | Results and conclusions | Study (Refs.) |
|---------------|--------------------------|------------|------------|------------------|------------|------------------------|---------------|
| Ishii et al (2010) | Role of AFP-producing cells as cancer stem cells | Notch1 | i) *In vitro*  
  ii) *In vivo*  
  iii) *Ex vivo* | i) HuCCT-1, OZ, SSP-25, RBE  
  ii) NOD/SCID mice  
  iii) Human ICC samples | Flow cytometry, single-cell culture assay, cell proliferation assay, anchorage-independent cell growth assay, H&E staining, sphere formation assay, RT-PCR, immunohistochemistry, histology | i) EGFP-positive cells: AFP upregulating Notch1 activation through NICD; increasing Notch 1 production.  
  ii) DAPT: Inhibiting activation of Notch1 signaling; reducing number of EGFP-positive cells.  
  iii) AFP-producing cells: Cancer-initiating cells. | (16) |
| Che et al (2016) | Role of Jagged1 in ICC | Notch2 | i) *In vitro*  
  ii) *In vivo*  
  iii) *Ex vivo* | i) HUCCT-1, KKU-156  
  ii) FVB/N mice  
  iii) Human ICC samples | Immunohistochemistry, RT-qPCR, western blotting, vimentin staining, Picro-Sirius Red staining, histology | Jagged1 co-expression and AKT activation: Increasing Notch2 expression and Hes1 proteins; inducing ICC development/progression. | (27) |
| Ding et al (2016) | Oncogenic potential of IDH1R132C (IDH1 mutant gene) in ICC development | Notch1 | *In vivo* | FVB/N mice | Immunohistochemistry, Picro-Sirius red staining, histology | Combination of IDH1R132C, shP53 and NICD1: Stimulating ICC development independent of AKT/mTOR and Ras/MAPK signaling. | (25) |
| Guest et al (2016) | Notch3 signaling in CCA using thioacetamide driven model | Notch3 | i) *In vivo*  
  ii) *Ex vivo* | i) Rat, CK19CreYFPp53<sup>−/−</sup> mice  
  ii) Human CCA samples, non-cancerous liver samples | PCR array, RT-qPCR, western blotting, immunohistochemistry, immunofluorescence, MTT assay, histology | i) Overexpression of Notch3: CCA formation/progression through inhibiting RBPJ, co-transcription factor with Notch signaling  
  ii) Activation of Notch3: CCA development, inhibited by shRNA. | (32) |
| Zhang et al (2018) | Role of Hippo pathway (Salvador-Warts-Hippo pathway) in AKT/Ras-driven hepatocarcinogenesis | Notch2 | i) *In vitro*  
  ii) *In vivo* | i) SNU-475, SK-HEP-1  
  ii) FVB/N mice | Histology, immunohistochemistry, western blotting, RT-qPCR, colony formation assay | i) Hippo pathway: Inactivated in AKT/Ras liver tumors, leading to Yap/TAZ nuclear localization  
  ii) Activation of the Hippo pathway or blocking of Yap/TAZ transcriptional activity: -AKT/Ras-induced tumor development: Delayed ICC-like lesion formation: Blocked | (28) |
| Author (year)        | Objective to investigate                                                                 | Notch type | Study type | Cell/animal used | Techniques                                                                 | Results and conclusions                                                                                      | Study (Refs.) |
|---------------------|------------------------------------------------------------------------------------------|------------|------------|------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|---------------|
| O'Rourke et al 2020 | Anti-CCA activity of Pan-GSI; transcriptomics of the Notch receptors and network analysis of major signaling pathways in CCA; Notch receptor engagement, γ-secretase modulation as a therapeutic approach | Notch1, Notch3 | i) In vitro ii) In vivo iii) Ex vivo | i) HuCCT-1, SNU-1079, SSP-25, RBE, SNU-308, YSCCC, SNU-869, SNU-245, SNU-1196, KMCH, WITT, SNU-478, KMBC ii) Mice iii) Human CCA tissues, surrounding liver tissues | Immunohistochemistry, RT-PCR, western blotting, Immunofluorescence, RNA-seq analysis, DNA methylation, CCA tissue microarray, histology | i) Hippo pathway: Notch2 expression downregulation ii) Overexpression of Lats2 or dnTEAD2: Inhibiting HCC growth; decreasing ICC-like markers and Notch2 expression i) Notch1: Significantly increased; imbalancing Notch pathway. ii) GSI cocktail: Effective anti-CCA | (23)          |
| Yamamoto et al 2017 | Interactions of the PI3K-AKT, YAP and Myc pathways in liver tumorigenesis and phenotypic determination | Notch1, Notch2 | i) In vivo ii) Ex vivo | i) C57BL/6J mice ii) Human HCC samples, human ICC samples | RT-qPCR, microscopy, immunohistochemistry, histology, Picro-Sirius red staining | i) PI3K-AKT pathway activation: Key determinant of cell differentiation ii) AKT activation by Myc and Notch1/2: Inducing high-grade CCA iii) AKT and YAP activation: Inducing low-grade CCA iv) AKT/Myc: Inducing low-grade CCA v) Co-activation of AKT, Myc and YAP: Inducing high-grade HCC vi) Co-activation of YAP and Myc: Inducing hepatoblast/stem-like cells | (12)          |
| Author (year)          | Objective to investigate                                                                 | Notch type | Study type | Cell/animal used                                                                 | Techniques                                                                                                                                  | Results and conclusions                                                                                                                                                                                                 | Study (Refs.) |
|-----------------------|------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Xu et al (2019)       | Role of SNAIL in promoting EMT and metastasis in hepatocarcinogenesis                    | Notch2     | i) *In vitro* ii) *In vivo* iii) *Ex vivo* | i) HLE, SNU449 ii) FVB/N mice iii) Human HCC tissues, non-tumorous surrounding liver tissues | Macroscopy, histology, immunohistochemistry, Picro-Sirius red staining, immunofluorescence, western blotting                                                                             | i) Overexpression of SNAIL: Not associated with metastasis, but associated with CCA formation ii) SNAIL: CCA-like phenotype regulation in hepatocarcinogenesis via regulation of Yap and Notch. iii) SNAIL mRNA level: Strongly correlated with CCA marker expression | (29)          |
| Tschaharganeh et al   | Role of p53 in regulating Nestin in HCC and CCA                                          | Notch      | i) *In vitro* ii) *In vivo* iii) *Ex vivo* | i) Hep-3B, HuH-7, HepG-2 ii) Nestin promoter-GFP mice, FVB/N mice, p53 fl/fl mice, Alfp-Cre p53 fl/fl mice iii) Human HCC tissues, human HCC-CCA tissues, human CCA tissues | Immunohistochemistry, RT-PCR, histology, microarray, DNA sequencing, immunofluorescence, western blotting, luciferase assay, chromatin immunoprecipitation, co-immunoprecipitation, colony formation assay, microscopy | i) p53: Regulating expression of stem and progenitor cell-associated protein nestin (required for tumor initiation) ii) p53: Loss/mutation in the majority of human cancers; facilitating mature hepatocyte differentiation into nestin-positive progenitor-like cells (differentiate into HCC or CCA cells response to lineage-specific mutations targeting Wnt and Notch signaling) | (34)          |
| Wang et al (2018)     | Role of Notch signaling and Notch receptors in AKT/YAP-driven ICC formation               | Notch2,    | i) *In vitro* ii) *In vivo* | i) KKU-M-213, RBE, HuCCT-1, HLE, SNU-449, SNU-475 ii) R26-EYFP mice, FVB/N mice, FVB/N and Notch2fl/fl mice, FVB/N and Notch1fl/fl mice | Immunofluorescence, western blotting, immunohistochemistry, histology, RT-qPCR | i) AKT/YAP: Activating Notch cascade; inducing hepatocyte-derived ICC; decreasing tumor proliferation (with Notch signaling inhibition) ii) Ablation of Notch1: Delaying ICC tumorigenesis iii) Notch2: Essential for AKT/YAP-induced ICC development: Suppressing Notch2: Reducing tumor proliferation, Notch1 expression, SOX9-positive cell, JNK pathway; delaying ICC tumorigenesis | (13)          |
Table I. Continued.

| Author (year)          | Objective to investigate                          | Notch type | Study type | Cell/animal used                                      | Techniques                                                                 | Results and conclusions                                                                 |
|-----------------------|---------------------------------------------------|------------|------------|------------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Zhou *et al* (2013)   | Expression and role of Notch1 in cell migration in ICC | Notch1     | *In vitro* | Human ICC tissues, non-cancerous tissues             | RT-PCR, western blotting, bromodeoxyuridine incorporation analysis,          | iv) Notch2 deletion inactivation: Switching tumor phenotype from ICC to hepatocellular  |
|                       |                                                   |            |            | i) QBC939, RBE, ICC-9810                            | Rac activation assay, immunocytochemistry, migration assay, immunohistochemistry | adenoma-like lesions                                                               |
|                       |                                                   | i) In vitro|            | i) Human ICC tissues                                 | i) High expression of Notch1: ICC tissues/cell lines                        |
|                       |                                                   |            |            | ii) QBC939, RBE, ICC-9810                            | ii) Notch1: Activating Rac1, promoting cell migration                        |
|                       |                                                   |            |            |                                                     | iii) Rac1: Tumor cell invasion and migration                                |
|                       |                                                   |            |            |                                                     | iv) GSI: Downregulating Notch1 Rac1, inhibiting cell migration               |
| Wu *et al* (2014)     | Expression of Notch receptors in ICC              | Notch1, Notch2, Notch3, Notch4 | *In vitro* | Human ICC tissues, non-Cancerous tissues             |                                                                           |
|                       |                                                   |            |            |                                                     | i) Notch1 exhibited 82.9% immunostaining positivity: 51.2% low-grade immunoreactivity and 31.7% high-grade immunoreactivity |
|                       |                                                   |            |            |                                                     | ii) Notch2 exhibited 56.1% immunostaining positivity: 26.8% low-grade immunoreactivity and 29.3% high-grade immunoreactivity |
|                       |                                                   |            |            |                                                     | iii) Notch3 exhibited 39% immunostaining positivity: 34.1% low-grade immunoreactivity and 4.9% high-grade immunoreactivity |
|                       |                                                   |            |            |                                                     | iv) Notch4 exhibited 34.1% immunostaining positivity: 24.4% low-grade immunoreactivity and 9.8% high-grade immunoreactivity |
The role of Notch signaling in cancer pathogenesis and progression has also been demonstrated in several other types of cancer, including embryonal carcinoma (38), glioblastoma (39), melanoma (40), ependymoma (41), breast cancer (42), HCC (34), ovarian cancer (43), endometrial carcinoma (44), esophageal squamous cell carcinoma, gonadotroph pituitary adenomas (42), rhabdomyosarcoma (45), colon cancer (46), gastric cancer (47), gastrointestinal stromal tumors (48), anaplastic thyroid cancer (49), medullary thyroid cancer (50), pancreatic cancer (51), glioblastoma multiforme (52) and neuroendocrine neoplasms (53). The signaling molecules and pathways involved vary according to the type of cancer. Notch3, in addition to Notch1, appears to play an important role in breast cancer development and progression through its activation of cartilage oligomeric matrix protein expression (54).

Downregulation of Notch1 signaling by several interventions has been demonstrated to be a promising strategy for inhibition of CCA growth. These interventions include administration of cinobufagin (a traditional Chinese medicine extracted from parotid and skin glands of Chinese Toad) (21), xanthohumol (55), verteporfin-PDT (30), DAPT (23), PIK75 (PIK3CA-specific inhibitor), verteporfin, anti-Notch1 antibody (27), miRNA-34a (31) and small interfering (si)RNA LTβR (22). The downregulation of Notch1 siRNA expression reduces Notch1 levels, which results in inhibition of Notch signaling, suppression of cell proliferation, and promotion of apoptosis (20,22,27,30,31,55). Verteporfin-PDT downregulates the mRNA expression of Notch1, Notch2 and Jagged1 (30); additionally, verteporfin can reduce YAP levels, decrease cell proliferation and induce apoptosis (14). Inhibition of MFAP5 using the γ-secretase inhibitor FLI-06 also suppressed Notch1 expression in CCA (20). Inhibition of Notch2 signaling using anti-Notch2 or anti-Jagged1 antibodies also suppressed Notch2 signaling (27) and miRNA-34a expression (31). Direct inhibition of Notch2 using miRNA-34a, PDT, anti-Notch2 or anti-Jagged1, and the Hippo pathway cascade decreases Notch2 levels, promotes apoptosis and inhibits cell proliferation. However, Notch1 and Notch2 signaling have been demonstrated to interact antagonistically with each other (27,36). Antagonists of Notch1 signaling can enhance Notch2 signaling, while Notch2 depletion can increase the levels of various components of the Notch1 signaling pathway, such as the endocannabinoids anandamide (AEA) and 2-arachidonylglycerol (2-AG), or anti-Notch1 and anti-Notch2 antibodies (27,34). AEA and 2-AG have been shown to exert different effects on Notch signaling. AEA, which has antiproliferative activity, upregulates Notch1 signaling via increasing the level of presenilin1, a catalytic subunit of γ-secretase. On the other hand, 2-AG, which has growth-promoting activity, upregulates Notch2 signaling via increasing the expression of presenilin 2, another catalytic subunit of γ-secretase. 2-AG activates Notch2 and enhances CCA cell proliferation (36).

| Study type | Notch type | Objective to investigate | Cell/animal used | Techniques | Results and conclusions |
|------------|------------|--------------------------|-----------------|------------|------------------------|
| Author (year) | Study (Refs.) | | | | |
| Notch1 and Notch4 were upregulated in ICC cells compared with non-tumor cells. | v) Notch1 and Notch4 were expressed in tumors sized >5 cm. vi) Notch4 was expressed in cases with serum carbohydrate antigen 125 >35 U/ml and was correlated with poor survival rate. | AFP, α-fetoprotein; CCA, cholangiocarcinoma; dnTEAD, double-negative TEA domain; EGFP, enhanced green fluorescent protein; EMT, epithelial-mesenchymal transition; ERT, epidermal-nerve-sensory transition; HCC, hepatocellular carcinoma; ICC, intrahepatic CCA; IDH1, isocitrate dehydrogenase 1; LATs, large tumor suppressor; NICD, Notch intracellular domain; Pan-GSI, Pan γ-secretase inhibitor; PDAC, pancreatic ductal adenocarcinoma; PIK3CA, PIK3 catalytic subunit alpha; RBPJ, recombination signal binding protein for immunoglobulin kappa J region; SNAIL, small family of transcriptional repressors; YAP, Yes-associated protein. |
The potential of the aforementioned interventions for the control of other types of cancer has also been demonstrated. These include cinobufagin for osteosarcoma (57), xanthohumol for hepatocarcinoma (58), FLI-06 for tongue cancer (59), GSI for glioblastoma cancer stem cells (60), T-cell for acute lymphoblastic leukemia (61), osteosarcoma (62) and...
Table II. Studies on modulators of Notch signaling in CCA.

| Author (year) | Modulators | Objective to investigate | Notch type | Study type | Cell/animal used | Techniques | Results and conclusions | Study (Refs.) |
|---------------|------------|--------------------------|------------|------------|-----------------|------------|-------------------------|---------------|
| Ren et al (2019) (2019) | Cinobufagin (from the parotid and skin glands of the Chinese toad) | Anti-CCA activity | Notch1 | i) *In vitro* ii) *In vivo* | i) QBC39, RBE ii) Nude mice | Cell counting assay, colony formation assay, flow cytometry, western blotting, histology | Inhibiting expression of Notch1, Hes1, Hes5, NICD; inducing CCA cell apoptosis; inhibiting tumor growth | (21) |
| Cerec et al (2009) | Verteporfin-PDT | Constitutive expression of the Notch signaling in CCA; anti-CCA activity of PDT and GSI; effect of verteporfin-PDT on Notch signaling | Notch1, Notch2, Notch3 | *In vitro* | TFK-1, HuCCT-1 | Cell proliferation assay, RT-qPCR | i) Decreasing mRNA levels of Notch1, Notch2, Jagged1, Notch3 in TFK-1 cell ii) Decreasing mRNA levels of Notch1, Notch2 and Jagged1; no effect on Notch3 mRNA in HuCCT-1 | (30) |
| El Khatib et al (2013) | GSI | Anti-CCA activity of GSI IX | Notch specific | i) *In vitro* ii) *In vivo* | i) TFK-1, SZ-1, EGI-1 ii) RSA26 NICD mice | WST assay, western blotting, MTT assay, wound healing migration assay, Transwell assay, anchorage-independent cell growth assay, flow cytometry, immunohistochemistry, histology qPCR, western blotting, immunofluorescence, immunohistochemistry, MTS assay, bromodeoxyuridine staining, immunoprecipitation, TUNEL assay, PCNA, histology | i) Inhibiting cell migration, invasion, colony formation; inducing CCA apoptosis ii) Inducing CCA cell cycle arrest (SubG1); delaying cell division process ii) Overexpressing Notch signaling and inactivating p53: Stimulating CCA development | (35) |
| Frampton et al (2010) | Endocannabinoids (AEA, 2-AG) | i) Opposing effects of AEA and 2-AG in differential activation of Notch signaling ii) Differential activation of Notch signaling associated with different types of presenilin in γ-secretase-containing cells | Notch1, Notch2 | i) *In vitro* ii) *In vivo* | i) Mz-ChA-1 ii) Balb/c nude mice | qPCR, western blotting, immunofluorescence, immunohistochemistry, MTS assay, bromodeoxyuridine staining, immunoprecipitation, TUNEL assay, PCNA, histology | i) AEA (antiproliferative activity): Increasing presenilin1 expression and activation of Notch1 signaling ii) 2-AG (growth-promoting activity) increasing presenilin2 expression and activation of Notch2 signaling iii) Notch1 signaling and Notch2 signaling: Antagonists of each other. | (36) |
| Author (year)        | Modulators                  | Objective to investigate                                                                 | Notch type | Study type | Cell/animal used | Techniques                                                                                           | Results and conclusions                                                                                                                                                                                                                                                                                                                                 |
|---------------------|-----------------------------|------------------------------------------------------------------------------------------|------------|------------|------------------|------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Gu et al (2016)     | Corilagin (from *Dimocarpus longan* Lour.) | Effect of corilagin on regulation of tumor development and occurrence through Notch signaling | Notch1     | *In vitro* | Mz-ChA-1, QBC-9939 | Flow cytometry, monolayer wound healing assay, RT-qPCR, western blotting, co-immunoprecipitation, histology | i) Inhibiting CCA cell proliferation, migration, invasion; promoting apoptosis (G2/M); inhibiting Notch1 and Notch signaling (Notch-mTOR, by reducing Hes1 mRNA through inhibiting Hes1 promoter activity)  
ii) Inhibiting CCA growth; repressing Notch1 and mTOR expression |
| Huang et al (2016)  | shRNA, SMIs targeting ASPH  | Molecular mechanism by which ASPH mediates CCA malignant phenotype                        | Notch      | *In vitro* | ETK-1, H-1, NEC, RBE, SSP-25, Nude mice, Fisher-344 | Western blot analysis, RT-PCR, Transwell invasion assay, cell growth assay, MTT assay, colony formation in soft agar assay, cancer stem cell sphere formation assay, histology | i) shRNA and SMIs: Inhibiting ASPH activity; downregulating Notch signaling; inhibiting cell proliferation/migration; enhancing caspase-3 cleavage; inducing apoptosis; suppressing tumor growth/progression |
| Huntzicker et al (2015) | Anti-Notch1, anti-Notch2, anti-Notch3, anti-Jagged1 antibodies | Role of Notch signaling when Notch receptors are physiologically activated via their ligands | Notch1, Notch2, Notch3 | *In vitro* | FVB/N mice, Human HCC samples | Immunofluorescence, RT-qPCR, histology, western blotting, immunohistochemistry, MRI, RNA-seq analysis | i) Notch1 inhibition: Reducing tumor burden (lowering large HCC-like tumors, but increasing CCA-like tumors)  
ii) Jagged1 acts as a ligand of Notch2: Inhibition of Notch2 and Jagged1: Reducing both HCC-like and CCA-like tumors  
iii) Notch3 inhibition: No significant effect on tumor burden |
| Author (year) | Modulators         | Objective to investigate                                                                 | Notch type | Study type | Cell/animal used                                                                 | Techniques                                                                                     | Results and conclusions                                                                 | Study (Refs.) |
|--------------|--------------------|-----------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------|
| Kwon et al (2017) | miRNA-34a         | Biological function and epigenetic regulation of miRNA-34a in CCA                        | Notch1, Notch2 | i) In vitro | i) CCLP-1, o) SG-231, II) HUCCT-1, III) TFK-1, H-69                              | Western blot analysis, i) RT-qPCR, cell proliferation assay, II) colony formation assay, III) bisulfide conversion PCR, melthylation-Specific PCR, chromatin immunoprecipitation assay, immunohistochemistry, histology, cell growth assay | i) miRNA-34a: Decreasing Notch1, Notch2 and Jagged1 levels; inhibiting tumor growth/colony formation II) EZH2-mediated H3K27 trimethylation and DNA methylation: Suppressing miRNA-34a expression independently III) EZH2 methylation: At 3 points of H3k7 of histone IV) DNA methylation: Silencing at CpG islands on the promoter of miRNA-34a gene | (31)        |
| Li et al (2015) | PIK3CA, YAP inhibitors (PIK75, verteporfin) | Concomitant activation of PI3K and YAP on CCA carcinogenesis                           | Notch2     | i) In vitro | i) HLF, SK/Hep-1, II) EGI-1, III) FVB/N mice                                 | Histology, i) immunohistochemistry, western blotting, cell proliferation assay, II) cell death detection, ELISA | i) Co-expression of PIK3CA/YAP: Activating downstream pathways (AKT/mTOR, ERK/MAPK, Notch2 signaling); Rapid tumor development II) PIK3CA and/or YAP inhibitors: Suppressing cell proliferation; inducing apoptosis | (14)        |
| Li et al (2019) | FLI-06, MFAP5 (Notch inhibitor) | Expression and function of FLI-06, MFAP5 on ICC                                       | Notch1     | i) In vitro | i) RBE, SSP-25, II) Nude mice, III) Human ICC samples, human HCC samples, human healthy samples | Immunohistochemistry, i) RT-qPCR, ELISA, II) western blotting, co-immunoprecipitation, western blotting formation assay, RNA-seq, qPCR ATAC-seq, GSEA analysis | i) MFAP5: Upregulated in patients with ICC. II) MFAP5: Promoting ICC cell proliferation (inhibiting p21, thus increasing CCND1/CDK4/6/CDK25A transcription, accelerating G0/G1 transition to S). III) MFAP5: Directly bound to Notch1 receptor upregulating Notch1 signaling; increasing chromatin accessibility, thus ICC aggressiveness. | (20)        |
| Author (year)       | Modulators                      | Objective to investigate                                                                 | Notch type | Study type | Cell/animal used                  | Techniques                                                                 | Results and conclusions                                                                                     | Study (Refs.) |
|---------------------|--------------------------------|----------------------------------------------------------------------------------------|-------------|------------|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|---------------|
| Sheng et al (2019)  | ALW-II-41-27, EphrinA1 (EPH receptor tyrosine kinase inhibitor) | Genetic alternations (EPHA2 mutation) during lymph node metastasis of ICC; potential mechanism and clinical strategy | Notch1      | i) *In vitro* |
|                     |                                |                                                                                        |             | ii) *In vivo* | i) HUVEC, CCLP-1, HUCC-1 |
|                     |                                |                                                                                        |             | iii) *Ex vivo* | ii) NOD/SCID mice, whole exome seq, RNA-seq, western blotting, RT-PCR, immunohistochemistry, ELISA, Transwell assay, PCR-based sanger seq, Cell proliferation assay, Pathway enrichment analysis, Transcriptome seq |
|                     |                                |                                                                                        |             |             | iii) Human ICC samples, primary cells from ICC tissues | i) EPHA2 mutant type D739N: activating Ser897 phosphorylation; promoting lymphatic metastasis via VEGF secretion (inducing tumor plasticity, lymphangiogenesis) ii) EPHA2 mutation: Enhancing AKT/RAS, activating Notch1 signaling, promoting lymphatic metastasis iii) EPHA2 mutation: Inhibited by ALW-II-41-27, but not ephrinA1 (major ligand of EPHA2). | (22)           |
| Scarzello et al     | Anti-LTβR                       | Relationship between LTβR and HCC, and ICC initiation                                         | Notch1      | i) *In vitro* |
|                     |                                |                                                                                        |             | ii) *In vivo* | i) HepG-2, Huh-1, HLE, Huh-7, Oz, KMBC, HuCCT-1, Mz-ChA-1 |
|                     |                                |                                                                                        |             |             | ii) C57/BL6 Jax mice | Gaussia luciferase assay, immunohistochemistry, western blotting, qPCR, flow cytometry, microarray analysis, Oil red O stain, histology, transcriptomics i) AKT/CAT: Initiating liver tumorigenesis; reducing tumor burden after LTβR expression ii) Anti-LTβR: Promoting tumor aggressiveness/progression; increasing AKT levels, thus upregulating NICD. iii) siRNA of LTβR: Decreasing AKT, NICD, CAT, Hes1 levels; reducing tumor progression i) Inducing cell cycle arrest; increasing p21 expression and inducing apoptosis and inhibiting cell proliferation and colony formation ii) Reducing Notch1 and AKT phosphorylation iii) Suppressing tumor growth/burden | (33)           |
| Walden et al (2017) | XN                             | Effect of XN on CCA                                                                        | Notch1      | i) *In vitro* |
|                     |                                |                                                                                        |             | ii) *In vivo* | i) CCLP-1, SG-231, CC-SW-1 |
|                     |                                |                                                                                        |             |             | ii) Athymic nude mice | MTT assay, colony formation assay, Flow cytometry, Western blot, Luminescence assay, Histology | i) Inducing cell cycle arrest; increasing p21 expression and inducing apoptosis and inhibiting cell proliferation and colony formation ii) Reducing Notch1 and AKT phosphorylation iii) Suppressing tumor growth/burden | (55)           |
### Table II. Continued.

| Author (year) | Modulators | Objective to investigate | Notch type | Study type | Cell/animal used | Techniques | Results and conclusions | Study (Refs.) |
|---------------|------------|--------------------------|------------|------------|------------------|------------|-------------------------|---------------|
| Wu et al (2014) | siRNA Notch1 | Effect of Notch1 expression in ICC tissues/cells | Notch1 | i) In vitro, ii) In vivo | i) RBE, ii) Human ICC tissues | qRT-PCR, Western blot, Cell counting assay, Colony formation assay, Transwell invasive assay, flow cytometry, DAPI staining | i) siRNA: Knocking down Notch1 activity and thus downregulating ICC proliferation/invasiveness; sensitizing ICC to 5-fluorouracil by suppressing ABCB-1 and MRP-1 expression ii) Notch1: Overexpressed in ICC cell membranes and cytoplasm. | (18) |
| Zender et al (2013) | DAPT | Function of Notch signaling in liver cancer formation | Notch1, Notch3 | i) In vitro, ii) In vivo, iii) Ex vivo | i) Mz-ChA-1, TFK-1, Egl-1, Hep-3B, HepG-2 ii) Nude mice, ROSA26 NICD mice, AlbCre mice iii) Human CCA tissues | Immunohistochemistry, Histology, Feulgen staining, Flow cytometry, Western blot, RT-PCR, Luciferase assay, Caspase3/7 assay, TUNEL staining | i) NICD overexpression in hepatocytes: Inducing endoduplication cycle and severely impairing cell proliferation ii) NICD overexpression in hepatic progenitor cells: Inducing CCA via cyclin E, leading to genetic instability iii) CCA: Upregulating Notch1 and Notch3 (correlated with cyclin E level) iv) DAPT: Decreasing Notch1 and Notch3 level, downregulating cyclin E expression, inducing apoptosis and tumor remission | (15) |

AEA, endocannabinoids anandamide; 2-AG, 2-arachidonoylglycerol; ASPH, aspartate-β-hydroxylase; ATAC-seq, Assay for Transposase-Accessible Chromatin with high-throughput sequencing; CCA, cholangiocarcinoma. DAPT, γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester; EZH2, enhancer of zeste homolog 2; GSEA, Gene Set Enrichment Analysis; GSI, γ-secretase inhibitor; HCC, hepatocellular carcinoma; LTβR, lymphotoxin β receptor; ICC, intrahepatic CCA; MFAp5, microfibrillar-associated protein 5; NICD, Notch intracellular domain; PDT, photodynamic therapy; PIK3CA, PIK3 catalytic subunit alpha; qPCR, quantitative PCR; RNA-seq, RNA-sequencing; YAP, Yes-associated protein; XN, xanthohumol; SMIs, small-molecule inhibitors; siRNA, small inhibitory RNA; shRNA, short hairpin RNA; miRNA, microRNA; Hes, hairy and enhancer of split.
triplet-negative breast cancer (63), and DAPT for glioma (64), colorectal cancer (65), cervical cancer (66), gastric cancer (67), head/neck squamous cell carcinoma (68), osteosarcoma (69), choriocarcinoma (70) and ovarian cancer (71). In addition, miRNA-34a has also been reported to inhibit the progression of pancreatic cancer and medulloblastoma (72,73), and siRNA interference has been reported to inhibit cell proliferation in glioblastoma multiforme (74).

In summary, overexpression/upregulation of the expression of Notch ligands (e.g., Jagged1) and Notch receptors (Notch1, Notch2, Notch3 and Notch4), as well as upregulation of the expression of upstream Notch signaling molecules, promotes CCA development and progression. Therefore, downregulation of Notch1 signaling through several interventions is a promising strategy for inhibition of CCA development and progression. However, further studies focusing on the application of these modulators of Notch signaling in a clinical setting must be performed in the future.

Acknowledgements

The authors thank Mr. Ethan Vindvamara (American molecular biologist; Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailand) for English editing of the manuscript.

Funding

The study was supported by the Research Team Promotion Grant, National Research Council of Thailand (grant no. NRCT 820/2563), Thammasat University (Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma) and Thammasat University Research Fund (contract no. TUFT 65/2564).

Availability of data and materials

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.

Authors' contributions

PV, WC and KN conceived the study and analyzed and interpreted the data. PN performed the background research, collected the data and wrote the manuscript. WC and KN critically revised the manuscript for important intellectual content. Data authentication is not applicable. All the authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

All the authors declare that they have no competing interests.

References

1. Khan SA, Tavolari S and Brandi G: Cholangiocarcinoma: Epidemiology and risk factors. Liver Int 39 (Suppl 1): S19-S31, 2019.
2. Mao Y, Huang X, Shuang Z, Lin G, Wang J, Duan F, Chen J and Li S: PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation. Cancer Med 7: 1285-1296, 2018.
3. Papsoutsoglou P, Louis C and Coulouarn C: Transforming growth factor-beta (TGF-beta) signaling pathway in cholangiocarcinoma. Cells 8: 960, 2019.
4. Panczewicz-Wojtkiewicz J: Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer. Cancer Med 5: 3572-3578, 2016.
5. Kandassamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK, Tellicherla D, Navarro JD, Mathivanan S, Equest C, et al: Notch signaling: A public resource of curated signal transduction pathways. Genome Biol 11: R3, 2010.
6. Hopfer O, Zwahlen D, Fey MF and Aebl S: The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 93: 709-718, 2005.
7. Stockhausen MT, Kristoffersen K and Poulsen HS: The functional role of Notch signaling in human gliomas. Neuro Oncol 12: 199-211, 2010.
8. Kontomanolis EN, Kalagasisoul S, Pouliousi S, Anthoulakis X, Georgiou P, Papamanolis V and Fasoulakis ZN: The notch pathway in breast cancer progression. ScientificWorldJournal 2018: 2415489, 2018.
9. Huang Q, Li J, Zheng J and Wei A: The carcinogenic role of the notch signaling pathway in the development of hepatocellular carcinoma. J Cancer 10: 1570-1579, 2019.
10. Sriirampong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SD and Ball DW: Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 61: 3200-3205, 2001.
11. Shao H, Cai L, Grichnik JM, Livingstone AS, Velazquez OC and Liu ZJ: Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene 30: 4316-4326, 2011.
12. Yamamoto M, Xin B, Watanabe K, Ooshoi T, Fujiji K, Chen X, Okada Y, Abe H, Taguchi Y, Miyokawa N, et al: Oncogenic determination of a broad spectrum of phenotypes of hepatocyte-derived mouse liver tumors. Am J Pathol 187: 2711-2725, 2017.
13. Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, et al: Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene 37: 3229-3242, 2018.
14. Li X, Tiao J, Cigliano A, Sini M, Calderaro J, Azoulay D, Wang C, Liu Y, Jiang L, Evert K, et al: Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget 6: 10102-10115, 2015.
15. Zender S, Nickeleit I, Wuestefeld T, Sörensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, Manns MP, et al: A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 23: 784-795, 2013.
16. Ishii T, Yasuchika K, Suemori H, Nakatsuji N, Ikai I and Uemoto S: Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma. Cancer Lett 294: 25-34, 2010.
17. Zhou Q, Wang Y, Peng B, Liang L and Li J: The roles of Notch1 expression in the migration of intrahepatic cholangiocarcinoma. BMC Cancer 13: 244, 2013.
18. Wu WR, Zhang R, Shi XD, Zhu MS, Xu LB, Zeng H and Liu C: Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. Oncol Rep 31: 2515-2524, 2014.
19. Gu Y, Xiao L, Ming Y, Zheng Z and Li W: Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo. Int J Oncol 48: 1868-1876, 2016.
20. Li H, Zhu XX, Li FX, Huang CS, Huang XT, Wang JQ, Guo ZX, Li SJ, Xu QC, Zhao W and Yin XY: MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway. J Exp Clin Cancer Res 38: 476, 2019.
21. Ren J, Wang S, Jin L, Ma F, Zhou D and Cai Q: Cinobufagin inhibits tumor growth by inducing apoptosis through Notch signaling pathways in human cholangiocarcinoma. Transl Cancer Res 8: 2461-2469, 2019.
22. Sheng Y, Wei J, Zhang Y, Gao X, Wang Z, Yang J, Yan S, Zhu Y, Zhang Z, Xu D, et al: Mutated EPHA2 is a target for combating lymphatic metastasis in intracerebral glioblastoma. Int J Oncol 52: 2019.

23. O’Rourke CJ, Matter MS, Nepal C, Caetano-Oliveira R, Ton PT, Factor VM and Andersen JB: Identification of a pan-gamma-secretase inhibitor response signature for notch-driven cholangiocarcinoma. Hepatology 71: 196-213, 2020.

24. Wu WR, Shi XD, Zhang R, Zhu MS, Xu LB, Yu XH, Zeng W, Wang H, et al: Genomic and transcriptional significance in regulation of Notch receptors in intracerebral glioblastoma. Int J Clin Exp Pathol 7: 3272-3279, 2014.

25. Ding N, Che L, Li XL, Liu Y, Jiang LJ, Fan B, Tao JY, Chen X and Ji JF: Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice. World J Gastroenterol 22: 2071-2080, 2016.

26. Huttner Z, Götz HH, Höttel K, Choy L, Ross J, Pau G, Pau G, Raskov S, Factum VM and Andersen JB: Identification of a notch signaling pathway in cholangiocarcinoma development in mice. Oncogenesis 5: e274, 2016.

27. Zhang S, Wang J, Wang H, Fan L, Fan B, Zeng B, Tao J, Li C, Chen X, Citri A, et al: Hippo cascade controls lineage commitment of liver tumors in mice and humans. Oncogenesis 5: e274, 2016.

28. Zhang S, Wang J, Wang H, Fan L, Bao T, Yao X, Zou M, Gao X, Zhang Y, Gao T and Guo W: Notch3 drives development and progression of cholangiocarcinoma. Proc Natl Acad Sci USA 113: 12250-12255, 2016.

29. Scardello AJ, Jiang Q, Back T, Dang H, Hodge D, Hanson C, Minnis-Lyons SE, Lu WY, Robson AJ, Gonzalez SF, et al: Notch signaling is required for cholangiocarcinoma development and progression through PTEN activation and dephosphorylation of Akt and FAK. Mol Med Rep 16: 2318-2324, 2017.

30. Dumont AG, Yang S, Reynolds A, Katz D, Trent JC and Hughes DP: Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. Carcinogenesis 33: 1674-1683, 2012.

31. Yu XM, Phan T, Patel PN, Jaskula-Sztul R and Chen H: Chrysin activates Notch1 signaling and suppresses tumor growth of glioblastoma cancer stem cells upon treatment with an inhibitor. Proteomics 11: 4529-4540, 2011.

32. Fan X and Lubman DM: Dose-dependent proteomic analysis of a p53-dependent Nestin regulation links Notch signaling pathways. PLoS One 10: e0121648, 2015.

33. Ding N, Che L, Li XL, Liu Y, Zhang Z, Wang H, Wang H, Zhang Y, Gao X, Zhang Y, Gao T and Guo W: Notch1 signaling is required for cholangiocarcinoma development in mice. World J Gastroenterol 22: 2071-2080, 2016.

34. Kong P, Shi R, Zhang R, Zhang Z, Wang X, Wu B and Zhong Z: Downregulation of YAP inhibits proliferation, invasion and increases cisplatin sensitivity in human hepatocellular carcinoma cells. Oncotarget 16: 585-593, 2018.

35. Wei X, Jia Y, Lou H, Ma J, Huang Q, Meng Y, Sun C, Yang Z, Li X, Xu S, et al: Targeting YAP suppresses ovarian cancer progression through inactivation of the PI3K/Akt/mTOR pathway. Oncotarget 42: 2768-2776, 2019.

36. Götte M, Greve B, Kelsch R, Müller-Uthoff H, Weiss K, Kharabi Masouleh B, Sibrowski W, Kiesel L and Buchwitz O: The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1. Int J Cancer 129: 2042-2049, 2011.

37. Cheng C, Cui H, Zhang L, Jia Z, Song B, Wang F, Li Y, Liu J, Kong P, Shi R, et al: Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma. Gigascience 5: 1, 2016.

38. De Salvo M, Raimondi L, Vella S, Adesso L, Ciarcipara R, Verginelli F, Panunzi C, Böttcher M, Milano GM, et al: Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells. PLoS One 9: e96238, 2014.

39. Singh S, Aracaroli J, Chen Y, Thompson DC, Messersmith W, Furunes A and Vassiliev V: 579-592, 2014.

40. Fox V, Gokhale PJ, Walsh JR, Matin M, Jones M and Andrews PW: Cell-cell signaling through NOTCH regulates human embryonic stem cell proliferation. Stem Cells 26: 715-723, 2008.

41. Chen J, Keshar S, Rooney C, Strack PR, Chen J, Shen H, Wu L and Griffin JD: Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor鹌鹑蛋. Genes Cancer 1: 822-835, 2010.

42. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Cabanjo AN, He J, Liu J and Zhang Y: Activation of Notch signaling is required for beta-catenin-mediated human melanoma progression. J Clin Invest 115: 3166-3176, 2005.

43. Puget S, Grill J, Valient A, Bieche I, Dantas-Barbosa C, Kauffmann A, Dessen P, Lacroix L, Goergen B, Job B, et al: Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas. J Clin Oncol 27: 1884-1892, 2009.
61. Tammam J, Ware C, Efferson C, O'Neil J, Rao S, Qu X, Gorenstein J, Angagaw M, Kim H, Kenific C, et al: Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol 158: 1183-1195, 2009.

62. Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y and Komiya S: Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 100: 1957-1965, 2009.

63. Li ZL, Chen C, Yang Y, Wang C, Yang T, Yang X and Liu SC: Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells. Int J Clin Exp Pathol 8: 4378-4387, 2015.

64. Liu X, Xu QR, Xie WF and Wang MD: DAPT suppresses the proliferation of human glioma cell line SHG-44. Asian Pac J Trop Med 7: 552-556, 2014.

65. Li H, Li D and Meng N: Effects of RUNX3 mediated Notch signaling pathway on biological characteristics of colorectal cancer cells. Int J Oncol 50: 2059-2068, 2017.

66. He G, Mu T, Yuan Y, Yang W, Zhang Y, Chen Q, Bian M, Pan Y, Xiang Q, Chen Z and Sun A: Effects of notch signaling pathway in cervical cancer by curcumin mediated photodynamic therapy and its possible mechanisms in vitro and in vivo. J Cancer 10: 4114-4122, 2019.

67. Peng X, Zhou J, Li B, Zhang T, Zuo Y and Gu X: Notch1 and PI3K/Akt signaling blockers DAPT and LY294002 coordinately inhibit metastasis of gastric cancer through mutual enhancement. Cancer Chemother Pharmacol 85: 309-320, 2020.

68. Zhao ZL, Zhang L, Huang CF, Ma SR, Bu LL, Liu JF, Yu GT, Liu B, Gutkind JS, Kulkarni AB, et al: NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. Sci Rep 6: 24704, 2016.

69. Qin J, Wang R, Zhao C, Wen J, Dong H, Wang S, Li Y, Zhao Y, Li J, Yang Y, et al: Notch signaling regulates osteosarcoma proliferation and migration through Erk phosphorylation. Tissue Cell 59: 51-61, 2019.

70. Tian Q, Xue Y, Zheng W, Sun R, Ji W, Wang X and An R: Overexpression of hypoxia-inducible factor 1α induces migration and invasion through Notch signaling. Int J Oncol 47: 728-738, 2015.

71. Jiang LY, Zhang XL, Du P and Zheng JH: γ-Secretase Inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro. Chin J Cancer Res 23: 140-146, 2011.

72. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, et al: MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4: e6816, 2009.

73. de Antonellis P, Medaglia C, Cusanelli E, Andolfi I, Liguori L, De Vita G, Carotenuto M, Bello A, Formiggini F, Galeone A, et al: MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One 6: e24584, 2011.

74. Wang J, Wang C, Meng Q, Li S, Sun X, Bo Y and Yao W: siRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth. Mol Biol Rep 39: 2497-2503, 2012.